In Cohort A,
pembrolizumab shrunk tumors by more than 30 percent in eight of 170 patients, or five percent, and stabilized the disease in 35, or 21 percent, of those previously treated for mTNBC.
Similarly,
pembrolizumab shrank tumors by at least a third in 24 percent of patients.
Not exact matches
In Cohort B — those who received
pembrolizumab as first - line therapy — 12 of 52 patients, or 23 percent, saw tumors
shrink by more than 30 percent, while the disease was stabilized in nine of them, or 17 percent.
«Immunotherapy drug effective for metastatic triple negative breast cancer:
Pembrolizumab shown to
shrink tumors — regardless of whether patient had prior treatment.»
In addition to helping patients live longer, more patients treated with
pembrolizumab responded to treatment and for a longer duration than those treated with chemotherapy; the objective response rate — the percentage of patients whose tumours
shrank or disappeared — was almost twice as high with
pembrolizumab: 21 % compared to 11 % on chemotherapy.
According to an international clinical trial led by Sylvia Adams, MD, associate professor of medicine, breast tumors
shrank by more than 30 percent in 12 (23 percent) of 52 patients who received
pembrolizumab as first - line therapy, and the disease stabilized in 9 additional patients (17 percent).